fda tirzepatide shortage Announced Removal of from the Drug List Important Announcement FDA Update on

Ion Layer NAD+ patches: high-dose NAD+ infusions without the needles, at-home, for a fraction of the cost of IVs

Clinical trials show that discontinuing tirzepatide leads to significant weight regain, with patients regaining approximately one-third of their weight loss

There is currently no FDA-approved oral tirzepatide, so any pill marketed as such is likely unsafe or unregulated

or Adults with a BMI of 27 or higher who have weight-related health conditions such as high blood pressure, type 2 diabetes, or high cholesterol

Flow Wellness provides clear dosing instructions to reduce confusion, improve safety, and help patients feel confident administering their medications